Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).

about

Immunotherapy in Advanced Non-small Cell Lung Cancer Patients: Ushering Chemotherapy Through the Checkpoint Inhibitors?

P2860

Q58699431-2B7F8C8B-39F6-4E1F-9B7E-6323B3B0A398

P2860

Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).

Item

http://www.wikidata.org/entity/Q55008531

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Implementation of immunotherap ...... mall cell lung cancer (NSCLC).

@en

Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer

@nl

type

Item

label

Implementation of immunotherap ...... mall cell lung cancer (NSCLC).

@en

Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer

@nl

prefLabel

Implementation of immunotherap ...... mall cell lung cancer (NSCLC).

@en

Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer

@nl

P1476

Implementation of immunotherap ...... mall cell lung cancer (NSCLC).

@en

P2093

Anna Tsiara

http://www.w3.org/2001/XMLSchema#string

Aristotelis Bamias

http://www.w3.org/2001/XMLSchema#string

Maria Kaparelou

http://www.w3.org/2001/XMLSchema#string

Meletios-Athanasios Dimopoulos

http://www.w3.org/2001/XMLSchema#string

Michalis Liontos

http://www.w3.org/2001/XMLSchema#string

Roubini Zakopoulou

http://www.w3.org/2001/XMLSchema#string

P2860

Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

Immune checkpoint inhibitors for nonsmall cell lung cancer treatment

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

P304

144

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21037/ATM.2018.02.07

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29862233

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

P932

5952012

http://www.w3.org/2001/XMLSchema#string

Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).

about

P2860

P2860

Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932